You searched for "DMO"

134 results found

Management of DMO and PDR in 2019

An evidence-based approach to the management of diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) in 2019 was outlined by Sobha Sivaprasad, UK, in presentations during the Diabetic Retina scientific session September 6 2019, at the 19th European Society...

The role of inflammation in the pathophysiology of DMO

Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...

Aflibercept, bevacizumab or ranibizumab for DMO

This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...

Management of diabetic macular oedema (DMO)

The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...

Intravitreal bevacizumab vs. triamcinolone in patients with DMO at the time of cataract surgery

This prospective, single masked randomised control trial (RCT) compared visual and anatomical outcomes when either intravitreal bevacizumab (BVB) or triamcinolone (TA) was administered at the time of cataract surgery and at subsequent review, if required, in patients with diabetic macula...

Strategies for managing neovascular AMD and DMO in routine clinical care

Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...

Two-year interim safety results of the 0.2ug/day FAC intravitreal implant for the treatment of DMO

This is a 24-month interim prospective observational study of 95 previously steroid challenged patients (115 eyes) receiving intravitreal 0.2ug/day fluocinolone acetaid (FAC) implant for diabetic macular oedema (DMO) treatment. The mean IOP for pre- and post- FAC implants were stable,...

Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders

This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...

Effect of heredity on risk of diabetic retinopathy

This study used survival analysis on 2199 patients who had reached vision-threatening diabetic retinopathy to investigate the contribution of heredity to diabetes together with other known risk factors for the development of either proliferative diabetic retinopathy (PDR) or diabetic macular...

Bromfenac versus betamethasone in diabetic macular oedema

This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...

Managing cataract surgery in a patient with diabetic maculopathy

A 56-year-old type 2 diabetic with previously treated bilateral diabetic maculopathy develops a cataract requiring surgery in the right eye. He has had grid laser previously, followed intermittently by intravitreal triamcinalone, Avastin and more recently Lucentis in both eyes. His...